In the last trading session, 13.27 million shares of the Iterum Therapeutics Plc (NASDAQ:ITRM) were traded, and its beta was 2.26. Most recently the company’s share price was $1.43, and it changed around -$0.45 or -23.94% from the last close, which brings the market valuation of the company to $32.48M. ITRM currently trades at a discount to its 52-week high of $2.50, offering almost -74.83% off that amount. The share price’s 52-week low was $0.64, which indicates that the current value has risen by an impressive 55.24% since then. We note from Iterum Therapeutics Plc’s average daily trading volume that its 10-day average is 12.17 million shares, with the 3-month average coming to 1.95 million.
Iterum Therapeutics Plc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended ITRM as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Iterum Therapeutics Plc is expected to report earnings per share of -0.2 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Iterum Therapeutics Plc (NASDAQ:ITRM) trade information
Instantly ITRM has showed a red trend with a performance of -23.94% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.3200 on recent trading dayincreased the stock’s daily price by 38.36%. The company’s shares are currently down -27.41% year-to-date, but still up 27.68% over the last five days. On the other hand, Iterum Therapeutics Plc (NASDAQ:ITRM) is 35.55% up in the 30-day period. We can see from the shorts that 0.21 million shares have been sold at a short interest cover period of 1.16 day(s).
Iterum Therapeutics Plc (ITRM) estimates and forecasts
Iterum Therapeutics Plc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -14.37 percent over the past six months and at a 59.80% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 33.30% in revenue this quarter, and will report an increase of 76.60% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 19.62%.
ITRM Dividends
Iterum Therapeutics Plc’s next quarterly earnings report is expected to be released in November.
Iterum Therapeutics Plc (NASDAQ:ITRM)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.81% of Iterum Therapeutics Plc shares, and 3.05% of them are in the hands of institutional investors. The stock currently has a share float of 3.10%. Iterum Therapeutics Plc stock is held by 16.0 institutions, with BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC being the largest institutional investor. By 2024-06-30, it held 0.0004% of the shares, which is about 66.0 shares worth $76.0.
